PAR General discussion, page-64

I've come around to this thinking now as well. Originally, I thought a CR was starting to look inevitable, and I even thought one might be announced last week ahead of the preso. Only after the preso had been digested, did I start to think that it's probably the least likely outcome now.

Quite aside from the cash on hand, as well as the sizeable rebate which Justin mentioned they were finalising, the options outlined didn't sound highly-encouraging if you were a fund awaiting a call from Paradigm for a cut-price placement anytime soon.

Personally - and considering now what Paul had to say about initial pharma interest, which I just posted on another thread - I think they are pretty confident of partnering well ahead of this becoming an issue.



If we're talking about funds to commercialise Zilosul....commercialising is a while away. A commercial strategy will be intrinsically linked to our partnerships. I reckon that is now our most likely source of cash injection in the next year or two. Just my opinion, and - as proven - i'm wrong plenty.

I had a little put aside in case of a CR, but instead I think i'll just buy on market soonish. I reckon large or small, we might all need to do that from now on.